Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
4.730
+0.240 (5.35%)
Aug 4, 2026, 1:29 PM EDT - Market open
Passage Bio Employees
Passage Bio had 24 employees as of December 31, 2025. The number of employees decreased by 36 or -60.00% compared to the previous year.
Employees
24
Change (1Y)
-36
Growth (1Y)
-60.00%
Revenue / Employee
n/a
Profits / Employee
-$1,569,833
Market Cap
15.17M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 24 | -36 | -60.00% |
| Dec 31, 2024 | 60 | 2 | 3.45% |
| Dec 31, 2023 | 58 | -27 | -31.76% |
| Dec 31, 2022 | 85 | -48 | -36.09% |
| Dec 31, 2021 | 133 | 59 | 79.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| Palatin Technologies | 29 |
| BioLineRx | 24 |
| Citius Pharmaceuticals | 23 |
| KALA BIO | 6 |
| Akari Therapeutics, | 6 |
| Pasithea Therapeutics | 5 |
| Cyclerion Therapeutics | 1 |
PASG News
- 13 days ago - Passage Bio Slides: Investor presentation - Filings
- 5 weeks ago - Passage Bio trading resumes - TheFly
- 5 weeks ago - Passage Bio Transcript: M&A announcement - Transcripts
- 5 weeks ago - Passage Bio Press release: M&A announcement - Filings
- 5 weeks ago - Passage Bio, Remix Therapeutics to combine in all-stock transaction - TheFly
- 5 weeks ago - Passage Bio trading halted, news pending - TheFly
- 5 weeks ago - Passage Bio and Remix Therapeutics Announce Merger Agreement - GlobeNewsWire
- 7 weeks ago - Guggenheim downgrades Passage Bio to Neutral, terminates coverage - TheFly